Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Recent Registrations
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
January
-
February
-
March
- April - May - June - July - August - September - Oktober - November - December |
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
-
2020
-
2021
- 2022
April 2022 - 112 products
NexoBrid
1 +
PR
PR
k.A.
Triskel INTEGRATED
SERVICES SA
A
FB
G
Rivaroxaban-Mepha
vascular 2.5 mg
Filmtabletten
56
PR
PR
k.A.
Rivaroxabanum 2.5 mg
Mepha Pharma AG
B
FB
G
Rivaroxaban-Mepha
vascular 2.5 mg
Filmtabletten
100
PR
PR
k.A.
Rivaroxabanum 2.5 mg
Mepha Pharma AG
B
FB
G
Rivaroxaban-Mepha
vascular 2.5 mg
Filmtabletten
196
PR
PR
k.A.
Rivaroxabanum 2.5 mg
Mepha Pharma AG
B
FB
G
Vitamin D3 Streuli 20`000
I.E. Weichkapseln
4
PR
PR
k.A.
Cholecalciferolum 20000 UI
Streuli Pharma AG
B
FB
G
Vitamin D3 Streuli 20`000
I.E. Weichkapseln
12
PR
PR
k.A.
Cholecalciferolum 20000 UI
Streuli Pharma AG
B
FB
G
CM
Zeller Wechseljahre
30
PR
PR
k.A.
Max Zeller Söhne AG
D
FB
G
CM
Zeller Wechseljahre forte
30
PR
PR
k.A.
Max Zeller Söhne AG
D
FB
G
CM
Zeller Wechseljahre
90
PR
PR
k.A.
Max Zeller Söhne AG
D
FB
G
CM
Zeller Wechseljahre forte
90
PR
PR
k.A.
Max Zeller Söhne AG
D
FB
G
Treprostinil Ideogen 1
mg/mL
20 ml
PR
PR
k.A.
Infusion solution: Treprostinilum 1 mg/ml
Ideogen AG
B
FB
G
Treprostinil Ideogen 2.5
mg/mL
20 ml
PR
PR
k.A.
Infusion solution: Treprostinilum 2.5 mg/ml
Ideogen AG
B
FB
G
Treprostinil Ideogen 5
mg/mL
20 ml
PR
PR
k.A.
Infusion solution: Treprostinilum 5 mg/ml
Ideogen AG
B
FB
G
Treprostinil Ideogen 10
mg/mL
20 ml
PR
PR
k.A.
Infusion solution: Treprostinilum 10 mg/ml
Ideogen AG
B
FB
G
Nubain 20 mg / 2 ml
5 x 2 ml
PR
PR
k.A.
Injection solution: Nalbuphini Hydrochloridum 20mg / 2ml
Maras AG
A
FB
G
Nubain 20 mg / 2 ml
10 x 2 ml
PR
PR
k.A.
Injection solution: Nalbuphini Hydrochloridum 20mg / 2ml
Maras AG
A
FB
G
Nubain 20 mg / 2 ml
20 x 2 ml
PR
PR
k.A.
Injection solution: Nalbuphini Hydrochloridum 20mg / 2ml
Maras AG
A
FB
G
Nubain 20 mg / 2 ml
50 x 2 ml
PR
PR
k.A.
Injection solution: Nalbuphini Hydrochloridum 20mg / 2ml
Maras AG
A
FB
G
Nubain 20 mg / 2 ml
100 x 2 ml
PR
PR
k.A.
Injection solution: Nalbuphini Hydrochloridum 20mg / 2ml
Maras AG
A
FB
G
Hukyndra 40mg/0.4ml
PR
PR
k.A.
Injection solution in prefilled syringe: Adalimumabum 40mg / 0.4ml
Spirig HealthCare AG
B
FB
G
Hukyndra 80mg/0.8ml
PR
PR
k.A.
Injection solution in prefilled syringe: Adalimumabum 80mg / 0.8ml
Spirig HealthCare AG
B
FB
G
Hukyndra 40mg/0.4ml
2
PR
PR
k.A.
Injection solution in prefilled syringe: Adalimumabum 40mg / 0.4ml
Spirig HealthCare AG
B
FB
G
Hukyndra 40mg/0.4ml
6
PR
PR
k.A.
Injection solution in prefilled syringe: Adalimumabum 40mg / 0.4ml
Spirig HealthCare AG
B
FB
G
CI
CM
GEM Bronchialpastillen neo
40
PR
PR
k.A.
Pastilles: 6 Active Agents
Tentan AG
E
FB
G
Cibinqo 50 mg
14
PR
PR
k.A.
Coated tablets: Abrocitinibum 50 mg
Pfizer AG
B
FB
G
Cibinqo 50 mg
28
PR
PR
k.A.
Coated tablets: Abrocitinibum 50 mg
Pfizer AG
B
FB
G
Cibinqo 50 mg
91
PR
PR
k.A.
Coated tablets: Abrocitinibum 50 mg
Pfizer AG
B
FB
G
Cibinqo 100 mg
14
PR
PR
k.A.
Coated tablets: Abrocitinibum 100 mg
Pfizer AG
B
FB
G
Cibinqo 100 mg
28
PR
PR
k.A.
Coated tablets: Abrocitinibum 100 mg
Pfizer AG
B
FB
G
Cibinqo 100 mg
91
PR
PR
k.A.
Coated tablets: Abrocitinibum 100 mg
Pfizer AG
B
FB
G
Ezetimib-Rosuvastatin-
Mepha 10 mg / 5 mg
30
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Ezetimib-Rosuvastatin-
Mepha 10 mg / 5 mg
90
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Ezetimib-Rosuvastatin-
Mepha 10 mg / 10 mg
30
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Ezetimib-Rosuvastatin-
Mepha 10 mg / 10 mg
90
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Ezetimib-Rosuvastatin-
Mepha 10 mg / 20 mg
30
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Ezetimib-Rosuvastatin-
Mepha 10 mg / 20 mg
90
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Ibu-Lysin Fairmed 200 mg
20
PR
PR
k.A.
Coated tablets: Ibuprofenum 200 mg
Fairmed Healthcare AG
D
FB
G
Ibu-Lysin Fairmed 400 mg
10
PR
PR
k.A.
Coated tablets: Ibuprofenum 400 mg
Fairmed Healthcare AG
D
FB
G
Olmesartan-HCT-Mepha Teva
20/12.5 mg
28
PR
PR
k.A.
Coated tablets: Hydrochlorothiazidum 12.5 mg
Mepha Pharma AG
B
FB
G
Olmesartan-HCT-Mepha Teva
40/12.5 mg
28
PR
PR
k.A.
Coated tablets: Hydrochlorothiazidum 12.5 mg
Mepha Pharma AG
B
FB
G
Olmesartan-HCT-Mepha Teva
20/12.5 mg
98
PR
PR
k.A.
Coated tablets: Hydrochlorothiazidum 12.5 mg
Mepha Pharma AG
B
FB
G
Olmesartan-HCT-Mepha Teva
40/12.5 mg
98
PR
PR
k.A.
Coated tablets: Hydrochlorothiazidum 12.5 mg
Mepha Pharma AG
B
FB
G
Olmesartan-HCT-Mepha Teva
20/25 mg
28
PR
PR
k.A.
Coated tablets: Hydrochlorothiazidum 25 mg
Mepha Pharma AG
B
FB
G
Olmesartan-HCT-Mepha Teva
40/25 mg
28
PR
PR
k.A.
Coated tablets: Hydrochlorothiazidum 25 mg
Mepha Pharma AG
B
FB
G
Olmesartan-HCT-Mepha Teva
20/25 mg
98
PR
PR
k.A.
Coated tablets: Hydrochlorothiazidum 25 mg
Mepha Pharma AG
B
FB
G
Olmesartan-HCT-Mepha Teva
40/25 mg
98
PR
PR
k.A.
Coated tablets: Hydrochlorothiazidum 25 mg
Mepha Pharma AG
B
FB
G
Rivaroxaban NOBEL 10 mg
10
PR
PR
k.A.
Coated tablets: Rivaroxabanum 10 mg
NOBEL Pharma Schweiz AG
B
FB
G
Rivaroxaban NOBEL 10 mg
30
PR
PR
k.A.
Coated tablets: Rivaroxabanum 10 mg
NOBEL Pharma Schweiz AG
B
FB
G
Rivaroxaban NOBEL 10 mg
100
PR
PR
k.A.
Coated tablets: Rivaroxabanum 10 mg
NOBEL Pharma Schweiz AG
B
FB
G
Rivaroxaban NOBEL 15 mg
15
PR
PR
k.A.
Coated tablets: Rivaroxabanum 15 mg
NOBEL Pharma Schweiz AG
B
FB
G
Rivaroxaban NOBEL 15 mg
28
PR
PR
k.A.
Coated tablets: Rivaroxabanum 15 mg
NOBEL Pharma Schweiz AG
B
FB
G
Rivaroxaban NOBEL 15 mg
98
PR
PR
k.A.
Coated tablets: Rivaroxabanum 15 mg
NOBEL Pharma Schweiz AG
B
FB
G
Rivaroxaban NOBEL 20 mg
14
PR
PR
k.A.
Coated tablets: Rivaroxabanum 20 mg
NOBEL Pharma Schweiz AG
B
FB
G
Rivaroxaban NOBEL 20 mg
28
PR
PR
k.A.
Coated tablets: Rivaroxabanum 20 mg
NOBEL Pharma Schweiz AG
B
FB
G
Rivaroxaban NOBEL 20 mg
98
PR
PR
k.A.
Coated tablets: Rivaroxabanum 20 mg
NOBEL Pharma Schweiz AG
B
FB
G
Sitagliptin-Metformin-
Mepha 50/500 mg
56
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Sitagliptin-Metformin-
Mepha 50/500 mg
196
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Sitagliptin-Metformin-
Mepha 50/850 mg
56
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Sitagliptin-Metformin-
Mepha 50/850 mg
100
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Sitagliptin-Metformin-
Mepha 50/850 mg
196
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Sitagliptin-Metformin-
Mepha 50/1000 mg
56
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Sitagliptin-Metformin-
Mepha 50/1000 mg
100
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Sitagliptin-Metformin-
Mepha 50/1000 mg
196
PR
PR
k.A.
Coated tablets: 2 Active Agents
Mepha Pharma AG
B
FB
G
Vitarubin Oral
30
PR
PR
k.A.
Coated tablets: Cyanocobalaminum 1 mg
Streuli Pharma AG
D
FB
G
Vitarubin Oral
100
PR
PR
k.A.
Coated tablets: Cyanocobalaminum 1 mg
Streuli Pharma AG
D
FB
G
Atomoxetin Xiromed 10 mg
7
PR
PR
k.A.
Capsules: Atomoxetinum 10 mg
Xiromed SA
A
FB
G
Atomoxetin Xiromed 18 mg
7
PR
PR
k.A.
Capsules: Atomoxetinum 18 mg
Xiromed SA
A
FB
G
Atomoxetin Xiromed 18 mg
28
PR
PR
k.A.
Capsules: Atomoxetinum 18 mg
Xiromed SA
A
FB
G
Atomoxetin Xiromed 25 mg
7
PR
PR
k.A.
Capsules: Atomoxetinum 25 mg
Xiromed SA
A
FB
G
Atomoxetin Xiromed 25 mg
28
PR
PR
k.A.
Capsules: Atomoxetinum 25 mg
Xiromed SA
A
FB
G
Atomoxetin Xiromed 40 mg
7
PR
PR
k.A.
Capsules: Atomoxetinum 40 mg
Xiromed SA
A
FB
G
Atomoxetin Xiromed 40 mg
28
PR
PR
k.A.
Capsules: Atomoxetinum 40 mg
Xiromed SA
A
FB
G
Atomoxetin Xiromed 60 mg
28
PR
PR
k.A.
Capsules: Atomoxetinum 60 mg
Xiromed SA
A
FB
G
Atomoxetin Xiromed 80 mg
28
PR
PR
k.A.
Capsules: Atomoxetinum 80 mg
Xiromed SA
A
FB
G
Atomoxetin Xiromed 100 mg
28
PR
PR
k.A.
Capsules: Atomoxetinum 100 mg
Xiromed SA
A
FB
G
Lenalidomid Viatris 2.5 mg
21
PR
PR
k.A.
Capsules: Lenalidomidum 2.5 mg
Mylan Pharma GmbH
A
FB
G
Lenalidomid Viatris 5 mg
21
PR
PR
k.A.
Capsules: Lenalidomidum 5 mg
Mylan Pharma GmbH
A
FB
G
Lenalidomid Viatris 7.5 mg
21
PR
PR
k.A.
Capsules: Lenalidomidum 7.5 mg
Mylan Pharma GmbH
A
FB
G
Lenalidomid Viatris 10 mg
21
PR
PR
k.A.
Capsules: Lenalidomidum 10 mg
Mylan Pharma GmbH
A
FB
G
Lenalidomid Viatris 15 mg
21
PR
PR
k.A.
Capsules: Lenalidomidum 15 mg
Mylan Pharma GmbH
A
FB
G
Lenalidomid Viatris 20 mg
21
PR
PR
k.A.
Capsules: Lenalidomidum 20 mg
Mylan Pharma GmbH
A
FB
G
Lenalidomid Viatris 25 mg
21
PR
PR
k.A.
Capsules: Lenalidomidum 25 mg
Mylan Pharma GmbH
A
FB
G
Colibiogen oral
100 ml
PR
PR
k.A.
Solution (oral): Escherichiae coli Lysatum (Stamm Laves) 760-870 mg/ml
Laves-Arzneimittel
Gesellschaft mit
beschränkter Haftung,
Ronnenberg,
Zweigniederlassung
Schötz
D
FB
G
IP
V/S
Nuvaxovid 5 ml
10
PR
PR
k.A.
Injektionsdispersion: Sars Cov-2 rs Nvx-Cov2373 5 µg
Future Health Pharma
GmbH
B
FB
G
Hukyndra 40mg/0.4ml
PR
PR
k.A.
Injektionslösung im Fertigpen: Adalimumabum 40mg / 0.4ml
Spirig HealthCare AG
B
FB
G
Hukyndra 40mg/0.4ml
2
PR
PR
k.A.
Injektionslösung im Fertigpen: Adalimumabum 40mg / 0.4ml
Spirig HealthCare AG
B
FB
G
Hukyndra 40mg/0.4ml
6
PR
PR
k.A.
Injektionslösung im Fertigpen: Adalimumabum 40mg / 0.4ml
Spirig HealthCare AG
B
FB
G
Midazolam Desitin 2.5
mg/0.5 ml
4 x 0.5 ml
PR
PR
k.A.
Lösung zur Anwendung in der Mundhöhle: Midazolamum 2.5mg / 0.5ml
Desitin Pharma GmbH
B
FB
G
Midazolam Desitin 5 mg/1 ml
4 x 1 ml
PR
PR
k.A.
Lösung zur Anwendung in der Mundhöhle: Midazolamum 5 mg/ml
Desitin Pharma GmbH
B
FB
G
Midazolam Desitin 7.5
mg/1.5 ml
4 x 1.5 ml
PR
PR
k.A.
Lösung zur Anwendung in der Mundhöhle: Midazolamum 7.5mg / 1.5ml
Desitin Pharma GmbH
B
FB
G
Midazolam Desitin 10 mg/2 ml
4 x 2 ml
PR
PR
k.A.
Lösung zur Anwendung in der Mundhöhle: Midazolamum 10mg / 2ml
Desitin Pharma GmbH
B
FB
G
Tenkasi 400 mg
3
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Oritavancinum 400 mg
A. Menarini GmbH
A
FB
G
Urocin 10 mg
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 10 mg
Regulix GmbH
A
FB
G
Urocin 10 mg
4
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 10 mg
Regulix GmbH
A
FB
G
Urocin 10 mg
5
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 10 mg
Regulix GmbH
A
FB
G
Urocin 10 mg
6
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 10 mg
Regulix GmbH
A
FB
G
Urocin 10 mg
10
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 10 mg
Regulix GmbH
A
FB
G
Urocin 10 mg
25
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 10 mg
Regulix GmbH
A
FB
G
Urocin 20 mg
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 20 mg
Regulix GmbH
A
FB
G
Urocin 20 mg
4
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 20 mg
Regulix GmbH
A
FB
G
Urocin 20 mg
5
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 20 mg
Regulix GmbH
A
FB
G
Urocin 20 mg
6
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 20 mg
Regulix GmbH
A
FB
G
Urocin 20 mg
10
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 20 mg
Regulix GmbH
A
FB
G
Urocin 40 mg
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 40 mg
Regulix GmbH
A
FB
G
Urocin 40 mg
4
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 40 mg
Regulix GmbH
A
FB
G
Urocin 40 mg
5
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 40 mg
Regulix GmbH
A
FB
G
Urocin 40 mg
6
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 40 mg
Regulix GmbH
A
FB
G
Urocin 40 mg
10
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zur intravesikalen Anwendung/Injektionslösung: Mitomycinum 40 mg
Regulix GmbH
A
FB
G
IP
CI
Bimatoprost Labatec 0.3
mg/ml
3 ml
PR
PR
k.A.
collyre en solution: Bimatoprostum
Labatec Pharma SA
B
FB
G
IP
Clobetasol Leman 0.5mg/g
125 ml
PR
PR
k.A.
shampoing: Clobetasoli Propionas
Leman SKL SA
B
FB
G
Tafluprost Santen 15 mcg / ml
30 x 0.3 ml
PR
PR
k.A.
unidose de collyre: Tafluprostum 15 µg/ml
Santen SA
B
FB
G
Tafluprost Santen 15 mcg / ml
90 x 0.3 ml
PR
PR
k.A.
unidose de collyre: Tafluprostum 15 µg/ml
Santen SA
B
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2022
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home